ELMSFORD, N.Y., May 11, 2015 /PRNewswire/
-- BioScrip®, Inc. (NASDAQ: BIOS) ("BioScrip"),
today announced the commencement of an exchange offer pursuant to
which it is offering to exchange up to $200,000,000 in aggregate principal amount
of 8.875% Senior Notes due 2021 (the "Exchange Notes"), which have
been registered under the Securities Act of 1933, as amended (the
"Securities Act"), for an equal aggregate principal amount of its
outstanding 8.875% Senior Notes due 2021 (the "Old Notes") that
were originally issued on February 11, 2014, in a transaction
exempt from registration under the Securities Act. The terms of the
Exchange Notes are substantially identical to the terms of the Old
Notes, except that the Exchange Notes have been registered under
the Securities Act and will not be subject to the transfer
restrictions and registration rights that related to the Old
Notes.
The exchange offer is being made to satisfy BioScrip's
obligations under a registration rights agreement entered into in
connection with the issuance of the Old Notes, and does not
represent a new financing transaction.
The exchange offer will expire at 5:00 p.m., New York
City time, on June 9, 2015, unless extended. Tenders of
Old Notes must be made before the exchange offer expires and may be
withdrawn any time prior to the expiration of the exchange
offer.
The terms of the exchange offer are set forth in a prospectus
dated May 7, 2015, and the associated letter of transmittal.
Copies of the prospectus, the associated letter of transmittal and
the other exchange offer documents may be obtained from the
exchange agent:
This press release is for informational purposes only and is
neither an offer to buy nor a solicitation of an offer to sell any
Old Notes or Exchange Notes. The exchange offer is being made only
pursuant to the exchange offer prospectus and letter of
transmittal, both of which are being distributed to holders of the
Old Notes and have been filed with the United States
Securities and Exchange Commission (the "SEC") as part of
BioScrip's Registration Statement on Form S-4 (File No.
333-201925), which was declared effective on May 6, 2015.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion
and home care management solutions. BioScrip partners
with physicians, hospital systems, skilled nursing facilities,
healthcare payors, and pharmaceutical manufacturers to provide
patients access to post-acute care
services. BioScrip operates with a commitment to bring
customer-focused pharmacy and related healthcare infusion therapy
services into the home or alternate-site setting. By collaborating
with the full spectrum of healthcare professionals and the
patient, BioScrip provides cost-effective care that is
driven by clinical excellence, customer service, and values that
promote positive outcomes and an enhanced quality of life for those
it serves. BioScrip provides its infusion services from
over 70 locations across 28 states.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bioscrip-announces-proposal-to-commence-exchange-offer-300080832.html
SOURCE BioScrip, Inc.